TRIPOD Checklist: Prediction Model Development

| Section | Item | Checklist description | Reported on Page Number/Line Number | Reported on Section/Paragraph |
| :---: | :---: | :---: | :---: | :---: |
| Title and abstract |  |  |  |  |
| Title | 1 | Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted. | page 1/line 1 | title page |
| Abstract | 2 | Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions. | page 3/line 55 | abstract |
| Introduction |  |  |  |  |
| Background and objectives | 3a | Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. | page 4/line 97 | introduction/paragraph 1 |
|  | 3b | Specify the objectives, including whether the study describes the development or validation of the model or both. | page 5/line 142 | introduction/paragraph 2 |
| Methods |  |  |  |  |
| Source of data | 4a | Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable. | page 5/line 154 | method/paragraph 2 |
|  | 4b | Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up. | page5/line 155 | method/paragraph 2 |
| Participants | 5a | Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres. | page 5/line 155 | method/paragraph 2 |
|  | 5b | Describe eligibility criteria for participants. | page5/line 154 | method/paragraph 2 |
|  | 5c | Give details of treatments received, if relevant. | page8/line 242 | result/paragraph 1 |
| Outcome | 6a | Clearly define the outcome that is predicted by the prediction model, including how and when assessed. | page 6/line 179 | method/paragraph 3 |
|  | 6b | Report any actions to blind assessment of the outcome to be predicted. | NA, no blind assessment | NA |
| Predictors | 7a | Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured. | page 6/line 179 | method/paragraph 3 |
|  | 7b | Report any actions to blind assessment of predictors for the outcome and other predictors. | NA, no blind assessment | NA |
| Sample size | 8 | Explain how the study size was arrived at. | page 8/line 238 | result/paragraph 1 |


| Missing data | 9 | Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method. | page 8/line 221 | method/paragraph 5 |
| :---: | :---: | :---: | :---: | :---: |
| Statistical analysis methods | 10a | Describe how predictors were handled in the analyses. | page8/line 221 | method/paragraph 5 |
|  | 10b | Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. | page 6/line 178 | method/paragraph 3 |
|  | 10d | Specify all measures used to assess model performance and, if relevant, to compare multiple models. | page8/line 229 | method/paragraph 6 |
| Risk groups | 11 | Provide details on how risk groups were created, if done. | page7/line 191 | method/paragraph 3 |
| Results |  |  |  |  |
| Participants | 13a | Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. | page 8/line 238 | result/paragraph 1 |
|  | 13b | Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome. | page 8/line 241 | result/paragraph 1 |
| Model development | 14a | Specify the number of participants and outcome events in each analysis. | page 18/line 488 | table 1 |
|  | 14b | If done, report the unadjusted association between each candidate predictor and outcome. | page 19/line 491 | table 2 |
| Model specification | 15a | Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point). | page 19/line 491 | table 2 |
|  | 15b | Explain how to the use the prediction model. | page 9/line 255 | result/paragraph 3 |
| Model performance | 16 | Report performance measures (with Cls) for the prediction model. | page 19/line 491 | table 2 |
| Discussion |  |  |  |  |
| Limitations | 18 | Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data). | page 12/line 340 | discussion/paragraph 3 |
| Interpretation | 19b | Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence. | page 11/line 308 | discussion/paragraph 2 |
| Implications | 20 | Discuss the potential clinical use of the model and implications for future research. | page 122/line 346 | discussion/paragraph 4 |
| Other information |  |  |  |  |
| Supplementary information | 21 | Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. | NA, not open to public | NA |
| Funding | 22 | Give the source of funding and the role of the funders for the present study. | NA, no funding | NA |

Article Information: http://dx.doi.org/10.21037/atm-20-1419
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

